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Impact of Heart Rate on Central
Aortic Pressures and Hemodynamics
Analysis From the CAFE (Conduit Artery
Function Evaluation) Study: CAFE-Heart Rate
Bryan Williams, MD, Peter S. Lacy, PHD, for the CAFE and the ASCOT
(Anglo-Scandinavian Cardiac Outcomes Trial) Investigators
Leicester, United Kingdom
Objectives The CAFE (Conduit Artery Function Evaluation) study showed less effective central aortic pressure lowering with
atenolol-based therapy versus amlodipine-based therapy in people with hypertension. The present study exam-
ined the importance of heart rate (HR) as a determinant of this effect.
Background Recent analyses have suggested that beta-blockers are less effective at reducing cardiovascular events than al-
ternative blood pressure (BP)-lowering therapies. There has been much debate about the mechanism for this
shortfall in benefit and specifically the role of HR lowering by beta-blockers.
Methods Central pressures were derived from brachial pressure and radial pulse wave analysis in 2,073 patients, and
7,146 measurements were recorded and analyzed over follow-up for up to 4 years.
Results There was no impact of HR on brachial systolic or pulse pressures; however, there was a highly significant inverse
relationship between HR and central aortic systolic and pulse pressures (p  0.001). This was dependent on a strong
inverse relationship between HR and augmentation index, indicative of increased wave reflection at lower HRs. Multi-
ple regression, adjusted for brachial BP, showed HR to be the major determinant of central pressures. Moreover, HR
and brachial BP accounted for 92% of the variability in central systolic and pulse pressures. Consequently, drug-
related differences in central aortic pressures were markedly attenuated after adjustment for HR.
Conclusions When comparing beta-blocker–based treatments with other BP-lowering strategies, HR reduction with beta-blockers is
a major mechanism accounting for less effective central aortic pressure reduction per unit change in brachial
pressure. (J Am Coll Cardiol 2009;54:705–13) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.088i
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peta-blockers have been a primary treatment for hyperten-
ion for many years. However, recent analyses have sug-
ested that beta-blocker–based therapy may be less effective
t preventing cardiovascular events when compared with
lternative blood pressure (BP)-lowering treatments in peo-
See page 714
le with hypertension (1–5). The United Kingdom National
reatment Guidelines in 2006 recommended that beta-
lockers should no longer be considered a suitable initial
herapy for the treatment of hypertension (6). There has
een much speculation about mechanisms for this shortfall
ontinuing Medical Education (CME) is available for this article. From the
epartment of Cardiovascular Sciences, University of Leicester School of Medicine,
nd the Leicester NIHR Cardiovascular Biomedical Research Unit, Leicester, United
ingdom.a
Manuscript received November 19, 2008; revised manuscript received February 11,
009, accepted February 23, 2009.n cardiovascular protection, especially stroke prevention,
ith beta-blockers in hypertensive patients. In the CAFE
Conduit Artery Function Evaluation) study, we have pre-
iously shown that the beta-blocker atenolol was less effec-
ive at lowering central aortic systolic and pulse pressures
PPs) when compared with alternative BP-lowering treat-
ent, despite similar brachial BP control (7). These find-
ngs are consistent with data from previous smaller-scale
tudies of shorter duration (8–11). Further analysis of the
AFE study suggested that central pressures may be an
ndependent predictor of clinical outcomes in hypertensive
atients (7). These findings suggest that the shortfall in
enefit from beta-blockers could relate to less effective
entral aortic pressure lowering, despite seemingly similar
ffects as other drugs treatments on brachial BP. If this is
he case, then important questions follow. What is the
echanism for the less effective reduction in central aortic
ressures with beta-blockers? Is this mechanism specific to
tenolol, or is it more broadly applicable to all beta-blockers?
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HR and Central Aortic Pressures August 18, 2009:705–13In the CAFE study, the main
difference in central aortic pres-
sures resulted from an increase in
pressure wave reflections (aug-
mentation index [AIx]) with
atenolol-based therapy, resulting
in augmentation of central aortic
systolic and PPs. Previous studies
ave demonstrated that AIx is inversely related to heart rate
HR) (12,13), suggesting that HR reduction may be the main
echanism accounting for less effective central pressure reduc-
ion with beta-blocker–based therapies.
These observations prompt further questions. How much of
he difference between atenolol- versus amlodipine-based ther-
py in the CAFE study could be attributed to the differences in
R between treatments? After adjusting for HR differences,
as there any residual impact of the 2 BP-lowering regimens
n central aortic pressures and hemodynamics?
The answer to these questions clearly has important impli-
ations with regard to the potential impact of therapeutic HR
anipulation on central aortic pressures and hemodynamics in
eople with hypertension. The present study thus examined
he hypothesis that HR was a major factor accounting for the
ifferential impact of BP-lowering treatments on central aortic
ressures and hemodynamics in the CAFE study.
ethods
he details of the CAFE study patient population and study
esign and procedures have been previously published (6) and
re briefly summarized below.
AFE study population and design. The CAFE study
as a substudy of the ASCOT (Anglo-Scandinavian Cardiac
utcomes Trial) study (14). Data on central aortic hemody-
amics was available from 2,073 participants recruited from 5
SCOT study centers in the United Kingdom and Ireland.
hese data form the basis of the present analysis and were
ollected over a median follow-up of 3 years. At baseline, the
atient population was hypertensive, of whom the majority was
reviously treated (90%). The patients also had 3 additional
ardiovascular risk factors to qualify for randomization to 1 of
BP-lowering strategies, using a prospective, randomized,
pen, blinded end point design: 1) a regimen of amlodipine,
dding perindopril as required; or 2) a regimen of atenolol,
dding bendroflumethiazide-K as required. Additional BP-
owering therapies were common to both treatment arms
ccording to a pre-specified algorithm (14). Antihypertensive
reatment was titrated to achieve a target BP (140/90 mm
g for people without diabetes and 130/80 mm Hg for
eople with diabetes). The patient demographics are shown in
able 1. All patients gave written informed consent, and
pproval for the study was granted by local research ethics
ommittees at each ASCOT study center. Ethical approval
as also granted by the United Kingdom Multi-Center Ethics
Abbreviations
and Acronyms
AIx  augmentation index
BP  blood pressure
HR  heart rate
PP  pulse pressureommittee. prachial BP, radial pulse wave analysis, and derivation of
entral aortic pressures and hemodynamic indexes. Bra-
hial BP was measured using a validated semi-automated
scillometric device (Omron 705CP, Omron, Kyoto, Japan) as
pecified in the ASCOT study protocol (15). The CAFE
tudy used radial artery applanation tonometry and pulse wave
nalysis (16,17) to derive central BPs and other parameters, as
aseline Demographics for the CAFE PopulationTable 1 Baseline Demographics for the CAFE Population
Atenolol Based
(n  1,031)
Amlodipine Based
(n  1,042)
Demographics and clinical characteristics
Women 208 (20.0%) 189 (18.3%)
Age (yrs)
60.0 367 (35.2%) 381 (37.0%)
60.0 675 (64.8%) 650 (63.0%)
Mean (SD) 62.9 (8.2) 62.6 (8.3)
White 892 (85.6%) 886 (85.9%)
Height (cm) 170.7 (8.7) 170.2 (9.4)
Weight (kg) 84.3 (15.7) 84.6 (14.7)
BMI (kg/m2) 29.1 (4.7) 29.0 (4.5)
Current smoker 267 (25.6%) 251 (24.3%)
Previous smoker 438 (42.0%) 448 (43.5%)
Never smoked 358 (34.4%) 352 (34.1%)
Systolic blood pressure (mm Hg) 161.0 (18.4) 159.9 (16.6)
Diastolic blood pressure (mm Hg) 92.6 (9.8) 92.4 (9.6)
Heart rate (beats/min) 71.2 (12.4) 71.8 (12.3)
Cigarettes/week among current smokers 82.0 (68.6) 92.6 (75.5)
Alcohol consumption (U/week) 11.8 (14.9) 11.5 (14.3)
Total cholesterol (mg/dl) 224.3 (38.7) 224.3 (42.5)
LDL cholesterol (mg/dl) 143.1 (34.8) 143.1 (34.8)
HDL cholesterol (mg/dl) 50.3 (15.5) 50.3 (15.5)
Triglycerides (mg/dl) 159.4 (88.6) 159.4 (88.6)
Glucose (mg/dl) 110 (38) 110 (38)
Creatinine (mg/dl) 1.08 (0.18) 1.09 (0.19)
Medical history
Previous stroke/TIA 101 (9.7%) 76 (7.4%)
Diabetes 251 (24.1%) 252 (24.4%)
LVH (echocardiogram or ECG)* 256 (24.6%) 237 (23.0%)
Atrial fibrillation 6 (0.6%) 9 (0.9%)
ECG abnormalities other than LVH† 272 (26.1%) 271 (26.3%)
Peripheral vascular disease‡ 59 (5.7%) 61 (5.9%)
Other relevant cardiovascular disease 27 (2.6%) 22 (2.1%)
Mean (SD) number of risk factors 3.7 (0.9) 3.7 (0.9)
Drug therapy
Previous antihypertensive treatments
None 100 (9.6%) 109 (10.6%)
1 496 (47.6%) 482 (46.8%)
2 446 (42.8%) 440 (42.7%)
Lipid-lowering therapy 120 (11.5%) 120 (11.6%)
Aspirin use 274 (26.3%) 244 (23.7%)
Left ventricular hypertrophy (LVH) by echocardiography was assessed as116 g/m2 in men and
104 g/m2 in women. Electrocardiogram (ECG) LVH was defined using either Cornell voltage
uration product (2,440) or Sokolow Lyon criteria (38 mm); †included evidence of left
entricular strain pattern, abnormal Q waves, evidence of left bundle branch block, and ST-T
hanges compatible with ischemic heart disease (ST-T depression, negative or biphasic T waves);
assessed using a validated questionnaire or from evidence of a recent history of surgical
ntervention for peripheral vascular disease.
BMI  body mass index; CAFE  Conduit Artery Function Evaluation; HDL  high-density
ipoprotein; LDL  low-density lipoprotein; TIA  transient ischemic attack.reviously described (Online Appendix).
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August 18, 2009:705–13 HR and Central Aortic PressuresThis method generates central aortic pressure waveforms
rom the radial pressure waveform using a previously vali-
ated transfer function (18,19). The central pressure waves
ere analyzed to identify the outgoing and reflected com-
onents and to calculate the AIx (i.e., the proportion of the
entral PP that is attributable to pulse wave reflection [P],
.e., [AIx  (P/PP)  100]) (Online Fig. 1). PP amplifica-
ion was calculated as the ratio of brachial to central PP. An
verage of 3.4 applanation tonometry measurements per pa-
ient were obtained at scheduled ASCOT study follow-up
isits. Typical interobserver variability at individual ASCOT
enters was 0.3 2.9 mm Hg for central systolic pressure and
.5  5.9% for AIx. This is consistent with our previously
ublished data using this technique (20).
tatistical methods. Statistical analyses were performed in
ollaboration with the ASCOT Study Coordinating Center at
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Figure 1 Relationship Between HR and Brachial or Central Pre
(A) Relationship between brachial (red circles) and central aortic (blue circles) sy Science, Goteborg, Sweden, using the SAS computer
rogram version 8.2 (SAS Institute Inc., Cary, North
arolina).
nalysis of the impact of HR on brachial BP, central
ortic pressures, and hemodynamic indexes. This analysis
sed 3 complementary strategies: 1) We examined the
elationship between HR as a continuous variable and
rachial BP, central aortic pressures, and hemodynamic
ndexes. Data from every CAFE study measurement (n 
,146) relating HR to these indexes, blinded to treatment
llocation, were included in the analysis. 2) Multiple step-
ise regression was performed to rank and quantify the
mpact of HR on brachial and central aortic pressures and
emodynamic indexes. 3) Data from the CAFE study was
djusted for HR to assess the residual impact of drug
herapy on central aortic pressures and hemodynamics.
Central, y = -0.3x + 141.7, R2 = 0.97, p<0.001
70 80 90 100
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Central, y = -0.3x + 64.0, R2 = 0.96, p<0.001
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between brachial (red circles) and central aortic (blue circles) pulse pressure and HR. Data are grouped into 10 beats/min heart rate increments (mean  SD).
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HR and Central Aortic Pressures August 18, 2009:705–13For univariate analyses, data were grouped into deciles of
R, and the relationship between HR and hemodynamic
ariables was analyzed using linear regression. Regression
ines were also fitted to plots of raw data. For multivariate
nalysis, stepwise multiple linear regression was used. Vari-
bles entered into the model were determined by linear
orrelation analyses. Continuous data variables between
P-lowering regimens were compared using nonpaired
tudent t tests. Where stated, data were adjusted for HR
sing general linear modeling before comparisons were
ade. Data are presented as mean (95% confidence interval)
r mean  SD as stated and a value of p  0.05 was
onsidered significant.
esults
he baseline characteristics of the CAFE study population
ccording to their randomized BP-lowering treatment allo-
ation are shown in Table 1. The 2 treatment groups were
ell matched with respect to their demographics, clinical
haracteristics, and previous medication.
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Figure 2 Relationship Between HR and the Difference Between
Relationship between heart rate (HR) and the difference between brachial and cenhe relationship between HR and brachial versus central
ressures. The relationship of HR with brachial and cen-
ral pressures is shown in Figure 1. The data encompass all
easurements performed during the CAFE study follow-
p. The data plots were very dense, thus for clarity of
resentation, the data were grouped into increments of
ncreasing HR (10 beats/min increments). Importantly, the
egressions of the relationships did not differ when compar-
ng the grouped and raw data plots. There was no significant
mpact of reducing HR on brachial systolic BP (0.6 mm
g per 10 beats/min decrease in HR) (Fig. 1A). By
ontrast, there was a 5-fold greater increase in central
ystolic pressure per unit change in HR (3.0 mm Hg per
0 beats/min decrease in HR). A similar dissociation
etween the impact of HR on brachial and central PP was
lso observed (Fig. 1B).
Figure 2 shows the differences between brachial and
entral pressures, plotted as a function of HR. Importantly,
t lower HRs, the difference between brachial and central
ressure progressively decreased, so that central pressure
pproached brachial pressure at the lowest HRs.
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August 18, 2009:705–13 HR and Central Aortic Pressureselationship between HR and components of the central
ressure waveform. To investigate the mechanisms involved
n the changes in central pressure with variation in HR, we
ext analyzed the components of the central pressure waveform
n relation to HR. There was minimal impact of HR on the
mplitude of the outgoing pressure wave (P1 height). How-
ver, there was a strong and significant inverse relationship
etween HR and the amplitude of pressure wave reflections
augmentation), which increased by 3 mm Hg per 10
eats/min reduction in HR (Fig. 3A). This finding suggests
hat the main impact of HR reduction was on the reflected
ave, rather than the incident pressure wave. Consistent with
his observation, there was a marked increase in AIx with
educing HR: 4.9% per 10 beats/min reduction in HR
Fig. 3B).
he relative contribution of HR to central pressures and
emodynamic variables. To further evaluate the contribu-
ion of HR to central pressures and hemodynamics, we
Outgoing, y = -0.03x + 32.9,
R2 = 0.002, p<0.001
Reflected, y = -0.3x + 32.5,
R2 = 0.3, p<0.001
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Figure 3 Relationship Between HR and Outgoing or Reflected P
(A) Relationship between heart rate (HR) and the outgoing pressure wave (P1 heig
the reflected pressure wave (augmentation, blue circles). (B) Relationship betweeerformed stepwise multiple linear regression (Table 2). After
ccounting for brachial BP, HR was the major determinant of
entral systolic and pulse pressures, accounting for 5% and 9%
f the variability in these parameters, respectively. HR was also
major determinant of pressure wave reflections (augmenta-
ion and AIx) and PP amplification, accounting for 26%, 34%,
nd 54%, respectively of the variability in these parameters. Of
mportance, in this analysis, the BP treatment regimen was a
uch less powerful determinant of central pressures and wave
eflections, accounting for no more than 0.5% of the variability
i.e., at least 10-fold less important than the impact of HR).
omparison of central pressures and hemodynamic vari-
bles between BP-lowering treatment arms before and after
djustment for HR. To further evaluate the relative contri-
ution of HR as a determinant of central pressures, the
ifferential impact of the 2 BP-lowering treatment regimens
n central pressures and wave reflections was resolved after
djusting the data for HR differences (Table 3). After HR
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HR and Central Aortic Pressures August 18, 2009:705–13djustment, the differences in central systolic and PPs between
reatment arms were no longer significant, and the differences
tepwise Multiple Regression Analysis of Central Pressures and HeTable 2 Stepwise Multiple Regression Analysis of Central Pres
Model and Predictors Regression Coefficient S
Central systolic pressure; adjusted r2  0.95, p  0.0001
Br SBP 1.11 0.0
HR 	0.25 0.0
Br PP 	0.28 0.0
Height 	0.06 0.0
Sex 	1.85 0.1
Age 0.08 0.0
Weight 	0.03 0.0
Treatment regimen 	0.76 0.0
Central PP; adjusted r2  0.94, p  0.0001
Br PP 0.72 0.0
HR 	0.27 0.0
Height 	0.06 0.0
Br SBP 0.11 0.0
Age 0.09 0.0
Sex 	1.85 0.1
Weight 	0.03 0.0
Treatment regimen 	0.78 0.0
Augmentation; adjusted r2  0.69, p  0.0001
Br PP 0.13 0.0
HR 	0.28 0.0
Sex 	2.92 0.1
Weight 	0.05 0.0
Br SBP 0.14 0.0
Age 0.12 0.0
Height 	0.08 0.0
Treatment regimen 	1.01 0.1
Smoker* 1.14 0.1
ECG other† 	0.58 0.1
Augmentation index; adjusted r2  0.55, p  0.0001
HR 	0.47 0.0
Height 	0.15 0.0
Sex 	4.83 0.2
Weight 	0.10 0.0
Br SBP 0.22 0.0
Br PP 	0.20 0.0
Age 0.21 0.0
Smoker 2.30 0.1
Treatment regimen 	1.46 0.1
ECG other 	1.05 0.1
PP amplification; adjusted r2  0.66, p  0.0001
HR 0.008 0.0
Height 0.002 0.0
Weight 0.001 0.0
Sex 0.046 0.0
Br SBP 	0.003 0.0
Br PP 0.003 0.0
Age 	0.003 0.0
Treatment regimen 0.018 0.0
ECG other 0.016 0.0
Smoker 	0.019 0.0
Current or recent (in the last year) smoker; †abnormalities on electrocardiogram (ECG) other th
vidence of left bundle branch block, and ST-T changes compatible with ischemic heart disease (
Br  brachial; HR  heart rate; PP  pulse pressure; SBP  systolic blood pressure; SE  stann augmentation, AIx, PP amplification, and the brachial- aentral aortic systolic and pulse pressure changes were mark-
dly attenuated. Taken together, these data suggest that HR is
ynamic Variablesand Hemodynamic Variables
F Value p Value R2 Change (%)
67,241 0.0001 87.3
5,630 0.0001 5.1
3,076 0.0001 1.6
123 0.0001 0.8
255 0.0001 0.2
232 0.0001 0.2
145 0.0001 0.1
93 0.0001 0.1
20,790 0.0001 82.5
7,176 0.0001 9
116 0.0001 1
634 0.0001 0.4
305 0.0001 0.3
266 0.0001 0.1
153 0.0001 0.1
100 0.0001 0.1
380 0.0001 29.3
4,240 0.0001 26.4
382 0.0001 6.8
178 0.0001 2.1
634 0.0001 1.9
319 0.0001 1.1
133 0.0001 0.5
99 0.0001 0.5
108 0.0001 0.5
30 0.0001 0.1
3,806 0.0001 34.4
140 0.0001 10.3
322 0.0001 2.5
226 0.0001 2.0
489 0.0001 1.3
287 0.0001 0.9
334 0.0001 1.6
135 0.0001 0.9
64 0.0001 0.5
29 0.0001 0.2
7,978 0.0001 53.7
124 0.0001 6.1
205 0.0001 1.3
200 0.0001 1.0
495 0.0001 0.8
315 0.0001 0.8
311 0.0001 1.3
65 0.0001 0.4
48 0.0001 0.3
61 0.0001 0.3
ventricular hypertrophy including evidence of left ventricular strain pattern, abnormal Q waves,
pression, negative or biphasic T waves).
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August 18, 2009:705–13 HR and Central Aortic Pressuresas the main determinant of the difference between central and
rachial pressures between treatment arms in the CAFE study.
iscussion
ithin a major clinical outcomes trial, this is the first study to
efine the impact of drug-related changes in HR, on central
ortic pressures and hemodynamics, in hypertensive patients.
ith over 2,000 patients and over 7,000 measurements, this
tudy had abundant statistical power to test its hypotheses. The
ata clearly demonstrate the powerful influence of HR, across
he physiological range, on central aortic pressures and wave
eflections in hypertensive patients, despite minimal effects on
rachial pressures.
We show that HR is inversely related to central aortic
ystolic and PPs. Lower HRs are also associated with reduced
P amplification; thus, at lower HRs, the central aortic systolic
ressure becomes closer to the brachial systolic pressure.
mportantly, there was minimal impact of HR on the outgoing
ressure wave height (P1 height), showing only a minor
ncrease with reduced HR. However, the inverse relationship
etween HR and indexes of central pressure wave reflection
i.e., augmentation) were much stronger, consistent with in-
reased wave reflection at lower HRs. Remarkably, the slopes
or the relationship between HR and central aortic systolic
ressure or magnitude of wave reflection (augmentation) were
dentical (3 mm Hg per 10 beats/min reduction in HR),
uggesting the importance of wave reflection in mediating the
R-related change in central aortic systolic pressure.
This finding that central pressure wave reflection is strongly
nfluenced by HR is supported by data from cross-sectional
tudies with data stratified by HR (21) and studies of cardiac
acing in humans, which suggested that AIx declines by 4% to
% per 10 beats/min increase in HR (12,13); the data for AIx
rom the present study are similar at 4.9% per 10 beats/min
eduction in HR. Interestingly, in a recent population study,
R was the most powerful modifiable predictor of AIx, central
ystolic pressure, and central PP (22).
mpact of HR versus treatment regimen. Multiple regres-
ion analysis confirmed the relative importance of HR after BP
tself, as a key determinant for all central hemodynamic
arameters. Moreover, adjusting the CAFE study data for HR
omparison of Central Pressures and Hemodynamic Variables BetwP-Lowering Treatment Arms Before and After Adjustment for H arTable 3 Comparison of Central Pressures an He odynamic VaBP-Lowering Treatment Arms Before and After Adjustm
Parameter
Unadjusted
Atenolol Amlodipine
Central systolic BP (mm Hg) 125.5 (124.7–126.3) 121.2 (120.5–12
Central pulse pressure (mm Hg) 46.4 (45.7–47.1) 43.4 (42.8–44.0
Augmentation (mm Hg) 15.4 (14.9–15.8) 11.5 (11.2–11.9
Augmentation index (%) 31.9 (31.3–32.4) 25.3 (24.8–25.9
Pulse pressure amplification 1.21 (1.2–1.21) 1.31 (1.3–1.32)
Brachial-central SBP (mm Hg) 8.3 (8.1–8.6) 12.0 (11.7–12.3
Brachial-central PP (mm Hg) 8.9 (8.6–9.1) 12.8 (12.5–13.1
alues are mean (95% confidence interval).
BP  blood pressure; other abbreviations as in Table 2.arkedly attenuated the difference in central pressures between she 2 BP-lowering treatment regimens. This suggests that this
ifference was primarily driven by differences in HR, although
ome residual effects remained. It is conceivable that unmea-
ured hemodynamic factors such as aortic stiffness and systemic
ascular resistance/remodeling, which could be differentially
nfluenced by drug treatments, may have accounted for some of
his residual variability (10,23).
echanisms for the inverse relationship between HR
nd central aortic pressures. We suggest 2 mechanisms
hat could account for the elevation in central pressures with
educed HR: first, reducing HR prolongs cardiac ejection
uration, but has no major effect on pulse velocity (7,24). This
ncreases the likelihood of a greater proportion of the reflected
ave appearing in late systole for any given pulse wave velocity.
eta-blockade also decreases the dP/dT during ventricular
jection, and this could delay the time to the peak of the
utgoing wave (10,25). This could also increase central systolic
ressure by increasing the probability of coincidence of the
eflected wave with late systole. Our finding of an increased
Ix with beta-blockade is consistent with this hypothesis.
Second, the less effective lowering of central aortic systolic
nd pulse pressures in patients with lower HRs is consistent
ith basic physiology. According to the derivation of Poi-
euille’s law, BP is the product of cardiac output  peripheral
esistance, where cardiac output is the product of stroke volume
nd HR. When HR is reduced by drug therapy (e.g., a
eta-blocker) mean arterial pressure is maintained by an
ncrease in stroke volume (26)—a phenomenon readily ob-
erved in patients with complete atrio-ventricular heart block.
n younger patients with compliant conduit arteries, this
ncrease in stroke volume can be accommodated. Indeed, in
onditioned athletes, a combination of increased aortic com-
liance and peripheral vasodilation prevents a marked rise in
Ix and central aortic pressure despite very low HRs and
arkedly increased stroke volumes (27). This represents per-
ect physiological adaptation to a reduced HR. In contrast,
ost hypertensive patients are not conditioned athletes, and in
he CAFE study were older with stiffened conduit arteries. In
his setting, a reduction in HR will result in the increased
troke volume being ejected into a less compliant proximal
orta, resulting in a rise in central aortic systolic and PPs. We
es Between
or Heart Rate
Adjusted
p Value Atenolol Amlodipine p Value
0.001 123.9 (123.1–124.6) 122.8 (122.1–123.6) 0.07
0.001 44.6 (43.9–45.2) 45.2 (44.6–45.9) 0.2
0.001 13.7 (13.4–14.1) 13.1 (12.8–13.5) 0.02
0.001 29.3 (28.8–29.8) 27.8 (27.3–28.3) 0.001
0.001 1.25 (1.24–1.26) 1.27 (1.26–1.28) 0.001
0.001 9.6 (9.3–9.8) 10.8 (10.5–11.0) 0.001
0.001 10.3 (10.0–10.5) 11.4 (11.2–11.7) 0.001eent Ratriabl
ent f
1.9)
)
)
)
)
)uggest that these are the 2 principal mechanisms accounting
f
s
t
c
e
b
a
s
s
I
s
w
a
t
p
s
u
i
o
c
s
b
l
t
d
t
r
f
S
H
c
f
b
r
o
p
b
c
l
s
p
I
f
s
m
t
r
o
e
H
d
s
c
p
M
b
p
o
c
d
b
a
a
t
t
i
b
c
c
fi
r
t
C
i
l
t
t
i
f
v
p
p
c
e
s
P
b
n
t
c
r
C
I
s
a
W
b
c
t
R
D
C
6
a
R
712 Williams and Lacy JACC Vol. 54, No. 8, 2009
HR and Central Aortic Pressures August 18, 2009:705–13or the inverse relationship between HR and central aortic
ystolic and PPs in the CAFE study. Moreover, we suggest
hat this inverse relationship would be accentuated if HR
hanges are restricted by drugs (i.e., beta-blockers) during
xercise, when the need to increase cardiac output could only
e met by an increase in stroke volume. These considerations
re of clinical importance given that central PP showed a
ignificant association with clinical outcomes in the CAFE
tudy and other studies (28,29).
s this data relevant to all beta-blockers? The present
tudy raises important questions as to whether similar effects
ould have been observed with beta-blockers other than
tenolol, notably vasodilating beta-blockers. Our data suggest
hat the impact of HR on central aortic pressure is very
owerful and consistent across the physiological range, irre-
pective of treatment allocation in this study. Other studies
sing invasive monitoring have shown that in patients receiv-
ng beta-blockers, the use of powerful vasodilators cannot
vercome the impact of HR reduction on wave reflection and
entral pressures (30). By contrast, a small number of previous
tudies comparing vasodilating and nonvasodilating beta-
lockers have suggested a more beneficial influence of vasodi-
ating beta-blockers on central pressures (31,32). However,
hese studies were small scale and underpowered, and the
ifferences in central pressures and wave reflections between
he different beta-blockers could be accounted for by the lesser
eductions in HR with vasodilating beta-blockers and/or dif-
erences in brachial BP.
tudy limitations. We recruited predominantly white men.
owever, our regression analysis suggests that the direction of
hange in central pressures and hemodynamics was the same
or women. It is unclear whether similar findings would have
een observed in other ethnic groups. Nevertheless, we cannot
ationalize why a mechanism that appears to be so dependent
n HR would be different in other ethnic groups. Our patient
opulation was also older, with a mean age of 63 years at
aseline. It is conceivable that in younger people with more
ompliant conduit arteries there would be a lesser impact of
ower HRs on central aortic pressure. These important con-
iderations need further evaluation.
We used noninvasive methods to derive central aortic
ressure from the radial pulse wave, calibrated to brachial BP.
t has to be considered whether the mathematical transfer
unction used to derive central hemodynamic indexes could be
ensitive to, or confounded by, changes in HR. The mathe-
atics involved are beyond detailed discussion here but use a
ransfer function to calculate central pressures from individual
adial pressure waveforms that is uninfluenced by the number
f waveforms as a function of time. Although, to our knowl-
dge, there have been no specific studies to assess impact of
R on central pressures comparing the methods here with
irect invasive measurements, there have been invasive mea-
urements of central aortic pressures in humans in response to
hanges in HR. In these studies, increasing HR via cardiac
acing has been shown to reduce central aortic pressure (12).
oreover, previous invasive studies have shown that beta-locker treatment increased (rather than reduced) central aorticressures (33). These directional changes are consistent with
ur findings. Furthermore, data from studies directly analyzing
arotid or invasively acquired central pressure waves have
ocumented reduced “pressure amplification” with beta-
lockade (24,33), consistent with our data. Other studies have
lso implicated HR as a major factor modulating pressure
mplification (13,21,34,35).
Finally, our study examines the association between on-
reatment HR and central pressures. It does not directly assess
he change in central pressure in response to a treatment-
nduced change in HR in individual patients. This would have
een difficult to do because of confounding due to associated
hanges in BP per se as a consequence of any treatment
hanges. Nevertheless, our multiple regression analysis identi-
ed HR to be a powerful independent factor influencing the
elationship between brachial and central aortic pressures, with
he latter being higher at lower HRs.
linical implications. These data have important clinical
mplications. There is a well-recognized association between a
ower HR and cardiovascular health reported from observa-
ional studies (36–38). This is often used as a justification for
herapeutic reductions in HR. In the setting of symptomatic
schemic heart disease and in patients with chronic stable heart
ailure, HR lowering by beta-blockade has been shown to be a
ery effective treatment strategy. However, the data from the
resent study question whether extending these assumptions to
eople with hypertension, especially older people with stiff
onduit arteries, is safe and appropriate. Moreover, because the
ffect of HR on central pressures seems so powerful, our data
uggest that there will be less effective central aortic systolic and
P reduction in older hypertensive patients with all beta-
lockers, or other drugs that lower HR. In this regard, the
ewer generation of vasodilating beta-blockers must be shown
o be as effective as alternative treatments in preventing
ardiovascular events before they can be considered as a suitable
outine treatment for older people with hypertension.
onclusions
n summary, the CAFE-Heart Rate study has demon-
trated that a lower HR is associated with higher central
ortic systolic and PPs in patients with treated hypertension.
e suggest that this is the major reason why beta-blocker–
ased therapy has been less effective at reducing cardiovas-
ular events, especially stroke, when compared with other
reatments in patients with hypertension.
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